Teva Pharmaceutical Industries' (TEVA) marketing authorization application for olanzapine long-acting injectable for the treatment of schizophrenia in adults has been accepted by the European Medicines Agency, the company said Thursday.
The drug, named TEV-749, aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.
The application is supported by an extensive clinical development program, in which the drug demonstrated efficacy, a systemic safety profile, and exposure consistent with oral olanzapine, Teva said.
Shares of Teva were down 1.4% in Thursday trading.
Price: $33.82, Change: $-0.50, Percent Change: -1.46%